论文部分内容阅读
目的:对患有肝硬化的相关乙肝患者进行恩替卡韦的相关治疗,尤其是在失代偿期中,主要观察治疗过程中有效安全性。方法:对有完整2年资料患有肝硬化的乙肝患者在相应的失代偿期进行相应恩替卡韦治疗。结果:在全部20例患者中在接受了恩替韦卡的治疗之后病情明显有所好转。结论:对患有肝硬化的乙肝患者进行恩替韦卡的相关治疗之后在治疗的安全有效性上都比较好,能够对乙肝病毒给与有效的抑制,从而对后续病情的复发起到了降低的作用。
OBJECTIVE: To provide entecavir-related therapy for patients with cirrhosis-related hepatitis B, especially during decompensation, and to observe the effectiveness and safety of the treatment. Methods: Patients with cirrhosis of hepatitis B who had complete 2 years of data were enrolled in the corresponding decompensated entecavir treatment. Results: The condition was significantly improved in all 20 patients after treatment with entrevivac. Conclusion: The treatment of hepatitis B patients with cirrhosis of the liver after entecavir treatment is relatively safe and effective, which can effectively suppress the hepatitis B virus and thus reduce the recurrence of subsequent disease effect.